From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Astra Zeneca, pipeline robust, share prophet indeed! Hold for bid details

By Robert Sutherland Smith | Wednesday 23 April 2014


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Were there dirty tricks afoot, when questions were raised about the strength of Astra Zeneca’s (AZN) pipeline? I recall it because I took the trouble to write a note in reply, on the 5th of March, rebutting the suggestion. I attributed this rumour to the fact that the share price had performed well and was full of profit having risen by more than a fifth since October 2013; thus presenting an opportunity for sell side business. How ironic that some six weeks later, the US drug company should be reported as sounding out the Anglo/Swedish AstraZeneca (AZN) about a bid it wishes to make for the company?



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

ANP

Anpario – a recovery Buy?...

Thursday »

Cat_Fixing_Lightbulb

Bearcast issue update: all should be well

 

ORCP

Oracle Power: Cynical Foul

Time left: 10:04:01